KALV
$27.00$0.00 (0.0%)
Last close · Data as of Jun 12, 2026
Price chart
Technical chartScreen technicals →Hidden because the last close is more than three trading days older than the latest prices of its class.
Daily closes.
| Date | Close |
|---|---|
| Apr 30, 2026 | $26.66 |
| May 1, 2026 | $26.65 |
| May 4, 2026 | $26.66 |
| May 5, 2026 | $26.71 |
| May 6, 2026 | $26.72 |
| May 7, 2026 | $26.72 |
| May 8, 2026 | $26.73 |
| May 11, 2026 | $26.71 |
| May 12, 2026 | $26.73 |
| May 13, 2026 | $26.80 |
| May 14, 2026 | $26.76 |
| May 15, 2026 | $26.73 |
| May 18, 2026 | $26.76 |
| May 19, 2026 | $26.77 |
| May 20, 2026 | $26.81 |
| May 21, 2026 | $26.77 |
| May 22, 2026 | $26.79 |
| May 26, 2026 | $26.81 |
| May 27, 2026 | $26.79 |
| May 28, 2026 | $26.77 |
| May 29, 2026 | $26.87 |
| Jun 1, 2026 | $26.94 |
| Jun 2, 2026 | $26.94 |
| Jun 3, 2026 | $26.95 |
| Jun 4, 2026 | $26.95 |
| Jun 5, 2026 | $26.95 |
| Jun 8, 2026 | $26.99 |
| Jun 9, 2026 | $26.99 |
| Jun 10, 2026 | $27.00 |
| Jun 11, 2026 | $27.00 |
| Jun 12, 2026 | $27.00 |
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 12 Jun 2026 close.
- 1M
- Stale
- 3M
- Stale
- 6M
- Stale
- 1Y
- Stale
- 5Y
- Stale
- Hidden because the last close is more than three trading days older than the latest prices of its class.
52-week range
Day change $0.00 (0.0%) from $27.00 to $27.00 · Last close Jun 12, 2026
News & filings
What KALV filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockNo rule stands out for this company on the data on file as of 12 Jun 2026.
- Prices are as of 12 Jun 2026; price-based points are paused until newer prices arrive.
- Financial statements for this company are not on file.
Prices to the 12 Jun 2026 close
Rule-based from financial data. Not advice.
About the company
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE).
Read moreShow less
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- 52-week high
- $27.00
- 52-week low
- $26.65
Growth
No growth data available.
No growth data available.
Monthly returns
Month-by-month returns of KALV across the years, with the seasonal pattern.
Market cap against peers
8 peers: same sector, nearest by size.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): KALV, Tvardi Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| KALVKALVthis company | — | — | — | — | — |
| INmune Bio Inc.INMB | $35.9M | -0.8x | 1.5x | -195.3% | -0.4x |
| Neonode Inc.NEON | $31.0M | 3.7x | 1.3x | 34.4% | 0.8x |
| Tvardi Therapeutics, Inc.TVRD | $28.9M | -1.6x | 1.4x | -87.0% | -0.3x |
| GoHealth, Inc.GOCO | $21.4M | -0.1x | 0.6x | -678.9% | -2.0x |
| Sleep Number CorporationSNBR | $8.1M | — | — | 22.8% | 105.2x |
| zSpace, Inc.ZSPC | $959.7k | -0.0x | -0.0x | 112.8% | -0.8x |
| Trinseo PLCTSEOF | $475.3k | -0.0x | -0.0x | 49.7% | 39.4x |
| ACCO Brands CorporationACCO | $0.00 | 0.0x | 0.0x | 6.2% | 5.1x |
| Peer median | — | -0.0x | 0.6x | 14.5% | 0.2x |
Year-to-date ROI
KALV since 1 January, against earlier years.
Historical volatility
KALV's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
No financial statement data available.
Learn while you research
Academy chapters picked for KALV and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 03 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read